Deutsche Bank (NYSE: DB) is reportedly close to finalizing a settlement with the Department of Justice. The stock price climbed $1.61 to close at $13.09.
Shares of Nutanix Inc. (Nasdaq: NTNX) more than doubled by leaping $21.00 to close at $37.00 in its market debut.
CalAmp Corp. (Nasdaq: CAMP) disappointed with sharply lower second quarter earnings of a penny per diluted share compared with 10 cents per diluted share in the year ago period that fell short of expectations. The stock price plummeted $2.46 to close at $13.95.
Cognizant Technology Solutions Corp. (Nasdaq: CTSH) disclosed an internal investigation into possible violations of the U.S. Foreign Corrupt Practices Act sending the stock price plummeting $7.37 to close at $47.63.
Threshold Pharmaceuticals Inc. (Nasdaq: THLD) reported disappointing interim data from two Phase 2 proof-of-concept clinical trials of tarloxotinib. The stock price tumbled 50 cents to close at $0.68.
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) reported positive results from a Phase IIb AURA-LV study for lupus nephritis lifting the stock price up 37 cents to close at $3.01.
Shares of Tabula Rasa Healthcare Inc. (Nasdaq: TRHC) soared $2.88 to close at $14.88 in its market debut.
Intra-Cellular Therapies Inc. (Nasdaq: ITCI) reported disappointing results from a Phase 3 trial of ITI-007 to treat schizophrenia prompting a downgrade. Shares of the biopharmaceutical plummeted $26.93 to close at $15.42.
Pacific Crest downgraded Fitbit Inc. (NYSE: FIT) from a Sector Weight rating to an Underweight rating sending the stock price tumbling $1.88 to close at $14.82.
The Food and Drug Administration's Division of Psychiatry Products placed a full clinical hold on Alcobra Ltd.'s (Nasdaq: ADHD) Investigational New Drug applications for MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome sending the stock price plummeting $2.11 to close at $2.51.